Erasca, Inc. (ERAS): Shareholders' Equity
$325.17M
As of 2025-12-31
$361.87M
As of 2026-06-30
-7.6%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $325.17M | -23.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $423.50M | +33.7% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $316.69M | -23.1% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $411.85M | -9.8% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $456.53M | n/m | 2023-03-23, Balance as of period end |
| 2020-12-31 | -$113.98M | n/a | 2022-03-24, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Erasca, Inc. (ERAS) | 2025-12-31 | $325.17M | -23.2% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | -$261.83M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $262.76M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $52.45M | -24.7% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $312.32M | -23.4% |
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $369.22M | +43.4% |
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $384.36M | +58.1% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $242.14M | -22.5% |
Compare ERAS, IRWD, TNGX, OTLC side by side · Screen every company in Pharmaceutical Preparations ↗